

RECEIVED

Sheet 1 of 2

SEP 30 2002

Express Mail No.: EL 500 576 114 US

TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

9516-026-999

APPLICATION NO.

10/001,281

APPLICANT

Hwu, Wen-Jen

FILING DATE

November 30, 2001

GROUP

1614

U.S. PATENT DOCUMENTS


INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CTO	AA	5,385,901	1/31/95	Kaplan et al.			
	AB	5,593,990	1/14/97	D'Amato			
	AC	5,629,327	5/13/97	D'Amato			
	AD	5,643,915	7/1/97	Andrulis, Jr. et al.			
CTO	AE	5,712,291	1/27/98	D'Amato			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

CTO	AF	Abramowicz et al. eds., "Drugs of Choice for Cancer Chemotherapy", The Medical Letter, 2000, Vol. 42. 83-92						
	AG	Boring et al., 1993, "Cancer Statistics", CA Cancer J. Clin. 43:7						
	AH	Burton et al., 1999, "New Chemotherapy Options for the Treatment of Malignant Gliomas", Curr Opin. In Oncol. 11:157-161						
	AI	Cohen et al., 2000, "Thalidomide in the Treatment of High Grade Gliomas",						
	AJ	Costa et al., 1998, "Thalidomide (TLD) and Pentoxifylline (PTX) Prevent the Development of Chronic Cardiomyopathy Provoked by Doxorubicin (DXR) in Rats Without Its Anti-Tumoral Effect", Blood 92(10:suppl. 1) : 235b (1998)						
	AK	D'Amato et al., 1994, "Thalidomide is an inhibitor of angiogenesis", Proc. Natl. Acad. Sci. 91:4082-4085						
	AL	Dive et al., 1989, "Inhibition of cellular esterases by the antitumor imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry", Cancer Chemother. Pharmacol. 25:149-155 (1989)						
	AM	Ehrenpreis et al., 1999, "Thalidomide Therapy for Patients with Refractory Crohn's Disease: An Open-Label Trial", Gastroenterology 117:1271-1277 (1999)						
	AN	Friedman et al., 2000, "Temozolomide and Treatment of Malignant Glioma", Clinical Cancer Research, 6:2585-2597						
	AO	Hvizdos et al., 1999, "Temozolomide", CNS Drugs 12: 237-243 (1999)						
	AP	Hwu et al., 2000, "New Approaches in the Treatment of Metastatic Melanoma: Thalidomide and Temozolomide", Oncology Supp 13:25-28						
	AQ	Hwu et al., 2001, "Treatment of Metastatic Melanoma in the Brain with Temozolomide and Thalidomide", THE LANCET Oncology 2: 634-635						
	AR	Ihde et al., 1992, "Chemotherapy of Lung Cancer", The New England Journal of Medicine 327:1434-1441 (1992)						
	AS	Kaba et al., 1997, "Recognition and Management of Gliomas", Drugs 53:235-244						
	AT	Klimek et al., 2000, "Systemic Chemotherapy", Cutaneous Melanoma, Clinics in Plastic Surgery 27:451-461						
	AU	Koch et al., 1985, "Thalidomide and Congeners as Anti-Inflammatory Agents", Prog. Med. Chem. 22:165-242						
	AV	Lipp et al., 2000, "Development of new antineoplastic agents with known and novel mechanisms of action", Krankenhauspharmazie 21:396-419						
	AW	Marx et al., 1999, "A Phase I/II Trial of Thalidomide as an Antiangiogenic Agent in the Treatment of Advanced Cancer" 18 Proc. Am. Soc. Clin. Oncology, 454a						
	AX	McCann et al., 1999, "Results for Breast Cancer Drugs under Spotlight", Drug Topics 41-42						
CTO	AY	McHugh et al., 1995, "The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen and antigen stimulated human peripheral blood mononuclear cell cultures", Clin. Exper. Immunol. 99: 160-167 (1995)						

C70	AZ	Mitchell et al., 1993, "Effect of Temozolomide and Dacarbazine on O6-alkylguanine-DNA Alkyltransferase Activity and Sensitivity of Human Tumor Cells and Xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea", <i>Cancer Chemother. Pharmacol.</i> , 32:59-63 (1993)
	BA	Moller et al., 1997, "Inhibition of IL-12 Production by Thalidomide", 159 <i>J. Immunol.</i> 159:5157-5161 (1997)
	BB	Moreira et al., 1993, "Thalidomide Exerts Its Inhibitory Action on Tumor Necrosis Factor α by Enhancing mRNA Degradation", <i>J. Expr. Med.</i> 177:1675-1680
	BC	Newlands et al., 1992, "Phase I Trial of Temozolomide (CCRG 81045: M & B 39831: NSC 362856", <i>Br. J. Cancer</i> , 65:287-291
	BD	Newton et al., 2000, "Novel Chemotherapeutic Agents for the Treatment of Brain Cancer", <i>Exper Opin Invest Drugs</i> 9:2815-2829
	BE	Packer et al., 2000, "Chemotherapy: Low Grade Gliomas of the Hypothalamus and Thalamus" <i>Pediatr Neurosurg</i> 32:259-263
	BF	Rubin et al., 1998, "Innovative Therapies for Pediatric Brain Tumors", <i>Curr Opin in Ped.</i> 11:39-46
	BG	Singhal et al., 1999, "Antitumor Activity of Thalidomide in Refractory Multiple Myeloma", <i>New England J. Med.</i> , 341(21): 1565-1571 (1999)
	BH	Solimando et al., 2000, "Epirubicin/Temozolomide", <i>Hospital Pharmacy</i> , 35:359-361 (2000)
	BI	Stevens et al., 1987, "Antitumor Activity and Pharmacokinetics in Mice of 8-Carbomoyl-3-methyl-imidazo(5,1-d) -1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a Novel Drug with Potential as an Alternative to Dacarbazine", <i>Cancer Res.</i> 47:5846-5852
	BJ	Vasiliauskas et al., 1999, "An Open Label Pilot Study of Low Dose Thalidomide in Chronically Active, Steroid Dependent Crohn's Disease", <i>Gastroenterology</i> 117:1278-1287 (1999)
	BK	Arance et al., 2000, "Three-Arm Phase II Study of Temozolomide in Metastatic Melanoma: Preliminary Results", <i>Oncology</i> 14(11):27 (Abstract #2257, Suppl. 12)
C70	BL	Hwu, 2000, "Commentary on Abstracts #2130 and 2257", <i>Oncology</i> 14(11):28-29 (Suppl. 12)
EXAMINER 		DATE CONSIDERED 5/12/03
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



RECEIVED
SEP 26 2002
TECH CENTER 1600/2900